Neal Bhatia, MD

Dermatology experts discuss BMI and other background comorbidities that can impact IL-23 inhibitors when treating plaque psoriasis.

Brad Glick, DO, AOCD, George Han, MD, PhD, and Neal Bhatia, MD, discuss year long term efficacy and safety data regarding the use of IL-23 inhibitors in patients with moderate to severe plaque psoriasis.

Dermatology experts discuss how IL-23 inhibitors fit into the current treatment landscape for plaque psoriasis.

George Han, MD, PhD, provides an overview of the long-term persistence of different biologic treatment options for plaque psoriasis.

Neal Bhatia, MD, discusses the impact of treatment mode of delivery on patient adherence and treatment selection for IL-23 inhibitors for plaque psoriasis.

Dermatology experts provide an overview of tildrakizumab, guselkumab, and risankizumab, agents approved for patients with plaque psoriasis.

Brad Glick, DO, AOCD, George Han, MD, PhD, and Neal Bhatia, MD, discuss communicating with patients about their plaque psoriasis treatment options.

George Han, MD, PhD, discusses the practical considerations of escalating treatment to the use of traditional oral systemic agents such as apremilast or methotrexate.

Neal Bhatia, MD, provides an overview of the spectrum of disease, topical choices, and transitioning to oral medications for the treatment of plaque psoriasis.

Brad Glick, DO, AOCD, George Han, MD, PhD, and Neal Bhatia, MD, discuss the current role of topical therapy and the use of non-biologic oral systemic and standard therapies for plaque psoriasis treatment.

Neal Bhatia, MD, FAAD, reviews the clinical implications of roflumilast, a newly approved topical agent for chronic plaque psoriasis treatment.

Neal Bhatia, MD, FAAD, provides an overview of the efficacy and safety results of the DERMIS 1 and DERMIS 2 trials for chronic plaque psoriasis treatment.

Neal Bhatia, MD, FAAD, discusses the current treatment landscape for patients with chronic plaque psoriasis, focusing specifically on PDE4 inhibitors.

Dermatology experts discuss the rapid expansion of the treatment armamentarium of plaque psoriasis and how has it shifted treatment approaches to plaque psoriasis.

Brad Glick, DO, AOCD, leads a discussion about the current therapeutic landscape and approval of various biologics therapies for the management plaque psoriasis.

Neal Bhatia, MD, addresses concerns about the long-term use of topical treatments in plaque psoriasis.

Neal Bhatia, MD, reviews roflumilast, a newly approved topical agent for plaque psoriasis treatment.

Neal Bhatia, MD, discusses patient adherence as one of the challenges with topical treatments in plaque psoriasis.

Neal Bhatia, MD, provides an overview of treatment options for patients with chronic plaque psoriasis, focusing specifically on the use of topical agents.

Key opinion leaders conclude their discussion on plaque psoriasis by commenting on the potential for research into the genetic origin of disease, possible biomarkers, and treatment options with greater efficacy.

A group of specialists discusses unmet needs in psoriatic disease including physician education about biologics and research about treatment options for pediatric patients, patients with malignancies, and patients who are pregnant.

A panel of experts builds a lively discussion on the evolving treatment landscape in plaque psoriasis and highlights the emergence of IL-23 inhibitors as a new class of biologic agents.

Thought leaders in the management of plaque psoriasis share personal insights into factors to consider when treating patients with IL-23 inhibitors, including when to switch biologic agents.

Erin Boh, MD, PhD, FAAD, guides the panel in a conversation about the phase 3 and long-term extension data from the VOYAGE 1 and VOYAGE 2 clinical trials of guselkumab in patients with moderate to severe plaque psoriasis.

George Han, MD, PhD leads a discussion on the pooled analysis of the phase 3 reSURFACE 1 and reSURFACE 2 clinical trials assessing the 5-year safety and efficacy of tildrakizumab in patients with moderate-to-severe psoriasis.

An expert in the management of plaque psoriasis, Erin Boh, MD, PhD, FAAD, highlights the importance of considering comorbidities, prior treatment, health care cost, and insurance when stratifying patients for treatment with biologics.

A specialist in the treatment of plaque psoriasis reviews the mechanism of action for IL-23 inhibitors and examines the dosing and administration of tildrakizumab, guselkumab, and risankizumab.

A panel of experts provides an overview of factors to consider when selecting therapy for patients with plaque psoriasis, including comorbidities, patient preference, and physician education.

Thought leaders in the management of plaque psoriasis consider the favorable safety profile of biologic agents compared to older therapies and highlight their role in the first-line treatment setting.

Neal Bhatia, MD, and Erin Boh, MD, PhD, FAAD, share key insights into the use of IL-12/23 and IL-17 inhibitors for plaque psoriasis as well as commonly comorbid conditions.